



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : L74999TG2016PLC109280

November 11, 2021

To,
Dept of Corporate Services,
BSE Limited,
PJ Towers, Dalal Street,
Fort, Mumbai-400001

Sub: Expansion of scope of GLP certification in Vanta Bioscience Limited
Ref: Reg 30 of SEBI (LODR) Regulations, 2015

We are pleased to inform that the National Good Laboratory Practice (GLP) certification and scope expansion audit has been successfully completed. The scope of expansion included additional capabilities in the area of toxicity studies (In Vitro sensitization, LLNA and additional battery of mutagenicity studies like HGPRT & MLA), In Vivo skin and eye irritation studies, Environmental toxicity; E-fate studies (Aquatic and terrestrial organisms, studies on behavior in Water, Soil and Air; Bioaccumulation) and Physical-chemical Testing (including five batch analysis). The scope of the said audit also included specific audit requests from USFDA & ECHA regulators.

The said certification granted by the NGCMA shall be valid for a period of three years.

The management is of the opinion that the said expansion of scope in certification will open up substantial market for the Company and will also result in increase in the scope of work/studies in Phychem etc., being received from existing long term clients of the Company. The said scope in expansion request was long due owing to delays caused by COVID 19 pandemic and has now been successfully completed.

In line with our previous intimation, the Trading Window for all designated persons as under Insider Trading Policy of the Company will open on November 15, 2021.

This is for your information and for dissemination to the general public at large.

For VANTA BIOSCIENCE LIMITED


DOPESH RAJA MULAKALA
MANAGING DIRECTOR

